SRR33346942
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.480
- OXIDATIVE_PHOSPHORYLATION+0.400
- MYC_TARGETS_V1+0.370
- CHOLESTEROL_HOMEOSTASIS+0.290
- TGF_BETA_SIGNALING+0.250
- MTORC1_SIGNALING+0.200
- FATTY_ACID_METABOLISM+0.130
- UNFOLDED_PROTEIN_RESPONSE+0.120
- ADIPOGENESIS+0.110
- ANDROGEN_RESPONSE+0.110
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.560
- ALLOGRAFT_REJECTION-0.480
- INFLAMMATORY_RESPONSE-0.480
- TNFA_SIGNALING_VIA_NFKB-0.480
- HEDGEHOG_SIGNALING-0.460
- IL6_JAK_STAT3_SIGNALING-0.460
- INTERFERON_GAMMA_RESPONSE-0.430
- MYOGENESIS-0.430
- INTERFERON_ALPHA_RESPONSE-0.370
- IL2_STAT5_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8943016 | — | — | 0.881 |
| 2 | SRR12202452 | — | — | 0.876 |
| 3 | BS_9NJHQE9F | Med | Medulloblastoma | 0.875 |
| 4 | 103802e1-b3a3-4c55-b094-5011798b6de3 | — | — | 0.874 |
| 5 | df4e44f9-ee22-43d3-911e-fd4bd826ec0c | — | — | 0.870 |
| 6 | MDT-AP-0395 | Med | Medulloblastoma | 0.862 |
| 7 | SRR12202451 | — | — | 0.857 |
| 8 | BS_K74PZET7 | Med | Medulloblastoma | 0.854 |
| 9 | X08d41e55.6d66.4e03.9dc3.3743f3da0453 | — | cohortA2 | 0.852 |
| 10 | TCGA-ZF-AA4U-01A-11R-A38B-07 | — | — | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.480 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.290 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.050 | Idelalisib | — uncovered |